Search Results
395 results
Your search is now limited to «Eli Lilly» expert search.
PharmaManufacturing 01/21/2019 17:30
An Eli Lilly treatment for advanced soft-tissue sarcoma missed the mark in a phase 3 study and will no longer be prescribed.
More from PharmaManufacturing:
PR Newswire 01/21/2019 16:15
Lilly will also conduct a conference call on that day with the investment community and media to further detail the company's financial performance.
More from PR Newswire:
Zacks.com 01/21/2019 13:33
Eli Lilly and Company ( LLY - Free Report) announced that a phase III study, evaluating Lartruvo (olaratumab) in combination with doxorubicin for treating metastatic soft tissue sarcoma (STS), failed to meet the primary endpoint of overall survival (OS ...
More from Zacks.com:
Pharmafile 01/21/2019 06:39
Lilly is committed to helping people who have soft tissue sarcoma and we will carefully study the detailed data in an effort to better understand the different results between the two trials.
More from Pharmafile:
(MENAFN - GetNews) Worldwidemarketreports.com has launched a new report on the Global Cosmetics and Pharma Market to provide readers with a clear view of the market's likely growth...
More from Middle East North Africa Financial Network (MENAFN):
Zymeworks Inc., a clinical-stage biopharmaceutical company developing multifunctional therapeutics, today reported the achievement of a new development milestone in its collaboration with Eli Lilly and Company (“Lilly.
More from Pharmaceutical Business Review:
NASDAQ 01/19/2019 19:52
Lilly said it is working with global regulators to determine the appropriate next steps for lartruvo.
More from NASDAQ:
Business Insider 01/18/2019 13:40
The inside story of Eli Lilly's 18-day race to secure an $8 billion deal in time for the 'Super Bowl' of healthcare Drugmaker Eli Lilly & Co. first approached the biotech Loxo Oncology about an acquisition on December 20, just weeks ...
More from Business Insider:
CNBC - Market Insider 01/18/2019 12:01
Eli LillyEli Lilly's stock fell 2.9 percent in midday trading after the company announced that a phase 3 study of Lartruvo failed.
More from CNBC - Market Insider:
Reuters.com 01/18/2019 10:46
On Friday, Lilly said the study did not confirm the clinical benefit of Lartruvo, used in combination with the standard-of-care chemotherapy doxorubicin, when compared to doxorubicin alone.
More from Reuters.com:
FiercePharmaManufacturing 01/18/2019 09:22
According to Lilly’s filing to the SEC (PDF), the company offered to buy Loxo for $230 a share in December, was rebuffed, and then upped the price 10 days later to $235.
More from FiercePharmaManufacturing:
FiercePharmaMarketing 01/18/2019 09:04
RELATED: Eli Lilly's sarcoma newcomer Lartruvo joins burgeoning oncology lineup And that, in turn, could interfere with Lilly’s 2019 revenue estimate of $25.3 billion to $25.8 billion, announced last month—a figure that beat average analyst expectations of ...
More from FiercePharmaMarketing:
pharmaphorum 01/18/2019 08:50
Shares in Eli Lilly were down in early trading after the US drugmaker said its cancer drug Lartruvo failed to meet main survival goals in a late stage trial, prompting the company to stop promoting the already-marketed medicine ...
More from pharmaphorum:
ENDPOINTS 01/18/2019 08:24
Lilly’s $LLY shares slipped about 3% pre-market.
More from ENDPOINTS:
WN.com 01/18/2019 08:15
Eli Lilly and Co said its cancer treatment Lartruvo failed to meet the main goal in a late-stage trial and it expects to take a charge in the first quarter of 2019, sending its shares down ...
More from WN.com:
About Lilly Oncology For more than 50 years, Lilly has been dedicated to delivering life-changing medicines and support to people living with cancer and those who care for them.
More from Healthcare Sales & Marketing Network:

Therapeutic Areas

Clinical Trials and Phases

Business Issues

Companies - Public

Companies - Venture Funded

Financial Results

Global Markets

Global Risk Factors

Government Agencies

Job Titles

Legal and Regulatory

Cell Receptors

Cells

Diagnostics and Therapeutics

Diseases

Drugs - Brand Names

Drugs - Generic

Enzymes

Genes

Health Care

Health and Wellness

Human Anatomy

Mechanisms of Action

Medical Devices

Proteins

Sources

Strategic Scenarios

Trends

Hints:

On this page, you see the results of the search you have run.  You may also view the following:

  •  Click on this drop-down menu on the right hand side of the page, to choose between the machine learning-produced Insights Reports, or the listing of concepts extracted from the results, in chart or list format. 


  •  View the number of search results returned for the search in each of your collections, and click on any of those numbers to view the entire listing of results from the chosen collection.

  •  Use the search adjustment drop-downs to change the scope, sorting, and presentation of your results.

  •  Show or hide the record’s caption (content description).

  •  Show actions that can be made with the search result record.

  •  Click on the Save button after running your search, to save it so that its results will be updated each time relevant new content is added to the designated collection. You may choose to be notified via search alerts.

Click here for more info on Search Results

Click here for more info on Machine Learning applications